Stocks In News: Dollar General Corp. (NYSE:DG), Arcos Dorados Holding Inc (NYSE:ARCO), WisdomTree Investments, Inc. (NASDAQ:WETF), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Technology Stocks News 9

Dollar General Corp. (NYSE:DG), a rival chain, has said it’s not interested in a merger with Family Dollar. And Wal-Mart wouldn’t have much use for the company’s stores because they’re too small for its Express format, Montagna said. Dollar General Corp. (NYSE:DG) stock performance was 7.35% in last session and finished the day at $62.25. Traded volume was 25.42million shares in the last session and the average volume of the stock remained 4.58million shares. The beta of the stock remained 0.25. Dollar General Corp. (NYSE:DG) insider ownership is 0.10%.

Arcos Dorados Holding Inc (NYSE:ARCO) rose more than 6 percent in the current trading session after Bank of America Merrill Lynch upgraded the Argentina-based company from “Underperform” to “Buy” with a price target of $14.16 per share for the stock, in a research report published this morning. ARCO has a market capitalization of $2.14 billion. Arcos Dorados Holding Inc (NYSE:ARCO) rose 7.91 percent to $10.37 Monday on volume of 1.14million shares. The intra-day range of the stock was $9.92 to $10.50. Arcos Dorados Holding Inc (NYSE:ARCO) has a market capitalization of $2.18billion.

WisdomTree Investments Inc. (NASDAQ:WETF) was upgraded by analysts at Morgan Stanley from an equal weight rating to an overweight rating. WisdomTree Investments, Inc. (NASDAQ:WETF)’s stock on June 09, 2014 reported a decrease of -0.65% to the closing price of $12.25. Its fifty two weeks range is $9.11 -$18.50. The total market capitalization recorded $1.63billion. The overall volume in the last trading session was 4.62million shares. In its share capital, WETF has 133.27million outstanding shares.

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) CEO Jean Jacques Bienaime unloaded 2,000 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $61.20, for a total transaction of $122,400.00. Following the transaction, the chief executive officer now directly owns 229,157 shares of the company’s stock, valued at approximately $14,024,408. On Monday, shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) dropped -0.37% to close the day at $61.51. Company return on investment (ROI) is -8.50% and its monthly performance is recorded as 8.33%. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) quarterly revenue growth is -20.32%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone